WebApr 11, 2024 · Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) released its earnings results on Tuesday, November, 30th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, … WebMar 24, 2024 · Cash balance of $18.9 million as of December 31, 2024; Signed out-licensing deal worth $42.7 million with Ewopharma; Phase III psoriasis topline data expected Q2 2024; Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Can-Fite’s Phase II study
Can-Fite BioPharma - CANF Stock Forecast, Price & News
Web2 days ago · Financial Performance. In 2024, CANF's revenue was 810,000, a decrease of -5.04% compared to the previous year's 853,000. Losses were -10.17 million, -19.36% … WebOct 6, 2024 · Can-Fite BioPharma Motti Farbstein [email protected] +972-3-9241114 Contacts. Can-Fite BioPharma Motti Farbstein [email protected] +972-3-9241114 Site Navigation. Home. Home; Submit a Press Release; bricklaying template
Can-Fite Announces Positive Top-Line Results from Piclidenoson …
WebCan·Fite BioPharma. is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The Company has an … WebApr 10, 2024 · The official website for the company is www.canfite.com. The company can be reached via phone at (723) 924-1114 , via email at [email protected] , or via fax at … covid cough first symptom